Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, et al. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis 2023 Sep 11:ard-2023-224449. doi: 10.1136/ard-2023-224449.
PMID: 37696589